EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma

Lauren R Schaff iD, Anna F Piotrowski, Elena Pentsova iD, Igor T Gavrilovic, Andrew Lin, Thomas J Kaley, Venissala Wongchai, Laleh Emadi-Paramkouhi, Juli Madzsar, Lillian Quinn, Ashley Gonzalez, Laura Breakey und 12 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf104 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Lauren R Schaff und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Weill Cornell Medical College, New York, New York, USA. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local, Lymphoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NINDS NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment options for recurrent/refractory central nervous system (CNS) lymphoma are limited but Bruton’s tyrosine kinase inhibitor ibrutinib has shown promise. To increase efficacy and reduce resistance, ibrutinib was combined with lenalidomide in a preclinical study and rituximab (R2I) in a phase Ib trial with expansion.

Methods

Ibrutinib 560 mg (dose level 1) or 840 mg (levels 2–4) was administered daily; lenalidomide was dosed on days 1–21 at 10 mg (level 1 + 2), 15 mg (level 3), or 20 mg (level 4) daily; rituximab 500 mg/m2 was administered every 28 days. Rituximab was given for 6 cycles, lenalidomide for 12 cycles, and ibrutinib ongoing.

Results

25 patients were enrolled (3 each into dose levels 1–3; 6 into level 4; and 10 into the expansion cohort at level 4). The median age was 67 years (range 41–85) and the median Eastern Cooperative Oncology Group 1 (range 0–2). Patients had a median of 2 prior regimens (range 1–5). Common adverse events were thrombocytopenia, rash, and lymphopenia. No aspergillosis or grade 5 toxicities were observed. After 12.8 months of median follow-up, 20/25 (80%) showed a response with a median time to best response of 60 days (range, 25–615). Median progression-free survival (PFS) was 4.3 months (95% CI: 2.4–not reached) with a PFS12m of 37% (95% CI: 22%–63%). Median overall survival has not been reached. Patients with rash during treatment had improved PFS (HR: 0.17, 95% CI: 0.05–0.55, P-value = .003).

Conclusions

R2I was tolerated well with high response rates and a short time to best respond. Median PFS was limited but 1/3 of patients had durable responses >12 months. This trial was registered at www.clinicaltrials.gov (NCT03703167).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalLymphomaHumansMiddle AgedAgedFemaleMaleLenalidomideAdultRituximabAged, 80 and overPiperidinesAdeninePyrimidinesPyrazolesFollow-Up StudiesSurvival RatePrognosisDrug Resistance, Neoplasm

Stichwörter der Autor:innen

CNS lymphomacentral nervous system lymphomaibrutiniblenalidomide

Substanzen

ibrutinibLenalidomideRituximabPiperidinesAdeninePyrimidinesPyrazoles

Autor:innen und Institutionen

  • Department of Neurology, Weill Cornell Medical College, New York, New York, USA.
  • Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Lauren R Schaff, Elena Pentsova, Anne S Reiner

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS
  • National Cancer Institute
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Schaff, L. R., Piotrowski, A. F., Pentsova, E., Gavrilovic, I. T., Lin, A., Kaley, T. J., Wongchai, V., Emadi-Paramkouhi, L., Madzsar, J., Quinn, L., Gonzalez, A., Breakey, L., Tang, S. S., Mendez, J. S., Malani, R., Nolan, C., Hatzoglou, V., Young, R. J., DeAngelis, L. M., …, & Grommes, C. (2025). Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf104

Vancouver

Schaff LR, Piotrowski AF, Pentsova E, Gavrilovic IT, Lin A, Kaley TJ, et al. Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf104

BibTeX
@article{Schaff2025,
  author = {Schaff, Lauren R and Piotrowski, Anna F and Pentsova, Elena and Gavrilovic, Igor T and Lin, Andrew and Kaley, Thomas J and Wongchai, Venissala and Emadi-Paramkouhi, Laleh and Madzsar, Juli and Quinn, Lillian and Gonzalez, Ashley and Breakey, Laura and Tang, Sarah S and Mendez, Joe S and Malani, Rachna and Nolan, Craig and Hatzoglou, Vaios and Young, Robert J and DeAngelis, Lisa M and Reiner, Anne S and Panageas, Katherine S and Francis, Jasmine H and Mellinghoff, Ingo K and Grommes, Christian},
  title = {Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf104}
}
Kostenlos starten →